The PERTE started in November 2021 with a public investment of €982 million, which was increased to just over €1.18 billion. The approval of the addendum means an additional €830 million, of which the Ministry of Science and Innovation will manage €600 million, and the rest will be managed by the Ministry of Health.
Morant stressed that the government believes in public health and has boosted this area with the greatest investment our country has ever had in science, innovation and digitalisation for the progress of healthcare.
"We want to research and design the therapies of the future, those that carry a name and a surname and use the genomic information of the patient and the disease to provide the best treatment. Our ambition is that any citizen of our country should receive this therapy through the National Health System," said the minister.
For his part, the Minister for Health, José Miñones, said that his ministry has executed 100% of the €273 million involved in this strategic plan, which demonstrates the great work carried out.
"Overall, the level of implementation of the PERTE for Vanguard health is very high, above 70%, showing that it is reaching the citizens, which is what we are looking for," said the minister.
The meeting of the Alliance Salud de Vanguardia was attended by representatives of the public administrations, scientific societies and business and patient associations to make progress in the implementation of this PERTE, in which 28 of the 39 planned actions have already been resolved, and a further 6 are currently under way.
Addendum to the PERTE for Vanguard Health
Among the actions of the Ministry of Science and Innovation that will be developed with the additional investment of the addendum, a joint project with the Ministry of Health, endowed with €20 million to improve early diagnosis and health care for rare diseases, stands out.
In the field of personalised medicine, a genomic diagnosis project is to be implemented, with a budget of €25 million, to be extended to daily clinical activity.
In addition, a financial support programme of €27 million will be made available to hospital-related research institutes to strengthen their research and technological development capacities.
The National Health System's clinical trials units will also be reinforced with €45 million to continue to be world leaders in clinical research and to bring it closer to all the territories of our country.
The internationalisation of Spain's industrial capacities in the health sector will also be strengthened with a €150 million Spanish contribution to the European Union's IPCEI.
In addition, work will be done to increase the size and industrial capacity of our companies with €30 million for co-investment, and a €298 million line of financing from the CDTI for companies in the health sector.
Last, €5 million will be allocated to strengthen the research capacities of the Instituto de Salud Carlos III (ISCIII).
Non official translation
